Baltimore, Maryland 21202


Purpose:

This study analyzes the gastrointestinal microbiome of appendiceal cancer patients with peritoneal spread scheduled to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Participants will provide fecal samples pre- and post-operatively.


Study summary:

Analysis of the human microbiome is an attempt to define how changes in the human microbiome are associated with health or disease. Eligible participants scheduled to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal cancer will provide fecal samples pre- and post-operatively. Investigators will analyze potential changes in the gastrointestinal microbiome and make comparisons to an age-matched healthy sample.


Criteria:

Inclusion Criteria: - Diagnosis of appendiceal cancer with peritoneal spread - Candidate for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) - ≥18 and ≤ 80 years of age - Eastern Cooperative Oncology Group performance status score of ≤2/Karnofsky performance status (KPS) ≥70% - Signed Institutional Review Board approved informed consent Exclusion Criteria: - <18 years of age - Pregnant women - Concurrent severe medical problems unrelated to malignancy


NCT ID:

NCT02599116


Primary Contact:

Principal Investigator
Armando Sardi, MD
Mercy Medical Center

Michelle Sittig, RN
Phone: 410-332-9294
Email: msittig@mdmercy.com


Backup Contact:

N/A


Location Contact:

Baltimore, Maryland 21202
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.